Develops small-molecule drug candidates for people with Parkinson’s disease and other neurological, metabolic and storage disorders, using a computational platform to identify compounds that alter disease-related proteins.
10-K for FY2025, filed Mar 26, 2026We are a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including…View ↗
GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people…View ↗
We use our computational target and drug discovery platform, Magellan™, to discover novel allosteric binding sites on proteins implicated…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$3.2MView ↗
8-K, filed Sep 28, 2026
On September 22, 2026, Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer, and principal accounting officer…View ↗
Broader Parkinson’s disease focus
The lead candidate was described as targeting a genetic form of Parkinson’s disease; the latest report describes it for Parkinson’s disease both with and without the associated mutation.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 26, 2026Our lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of GCase…View ↗
GT-02287 - our lead product candidate, for the treatment of Parkinson’s disease, is currently being evaluated in a Phase 1b study in people…View ↗
Narrower pipeline emphasis
The older report described programs in Parkinson’s and Gaucher disease, Krabbe disease, liver and lung disease, and oncology; the latest centers on advancing the Parkinson’s lead program while continuing other research programs.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 26, 2026We are leveraging our SEE-Tx® technology platform to develop a pipeline of novel small molecule drug candidates to address complex…View ↗
We are leveraging our Magellan™ technology platform to develop a pipeline of novel small molecule drug candidates to address complex…View ↗
Competes with Vanqua Bio, BIAL, Caraway Therapeutics, Prevail Therapeutics, and Voyager Therapeutics
10-K for FY2025, filed Mar 26, 2026The biotechnology and pharmaceutical industries are characterized by the rapid evolution of technologies and understanding of disease…View ↗
Loading...